Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Minerva Neurosciences Stock Quote

Minerva Neurosciences (NASDAQ: NERV)

$2.34
(-1.3%)
-$0.03
Price as of May 6, 2024, 4:00 p.m. ET

Minerva Neurosciences Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
NERV -61.00% -95.75% -46.83% -95%
S&P +25.25% +79.92% +12.46% +163%

Minerva Neurosciences Company Info

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.